[Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target...

Area of Science:

• Oncology
• Immunotherapy
• Renal Cell Carcinoma Research

Background:

• Cytokine therapy for metastatic renal cell carcinoma (mRCC) is largely superseded by targeted therapies.
• Checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1) represent a promising second-generation immunotherapy.
• Previous studies suggest PD-L1 protein expression correlates with poor prognosis and response to anti-PD-1 therapy in mRCC.

Purpose of the Study:

• To analyze the Cancer Genome Atlas (TCGA) KIRC dataset for associations between PD-L1 and PD-1 mRNA expression and clinical pathological parameters in clear cell renal cell carcinoma (ccRCC).
• To evaluate the correlation of PD-L1 and PD-1 mRNA expression with patient survival in ccRCC.

Main Methods:

• Utilized TCGA KIRC network data for genome-wide mRNA expression analysis.
• Investigated PD-L1 (CD274) and PD-1 (PDCD1) mRNA expression in 417 primary ccRCC specimens.
• Correlated mRNA expression levels with clinical pathological parameters and patient survival data.

Main Results:

• PD-L1 mRNA expression in primary ccRCC showed no significant association with unfavorable clinical parameters.
• A positive correlation was observed between PD-L1 mRNA expression and improved patient survival (HR=0.59, p=0.006).
• Findings partially contradict the prevailing understanding of PD-L1's role in ccRCC.

Conclusions:

• The study highlights the need for further investigation into PD-L1 and PD-1 expression at both mRNA and protein levels in ccRCC.
• Evaluating clinical significance requires appropriately sized patient cohorts to validate these findings.
• Current understanding of PD-L1's role in ccRCC immunotherapy may need re-evaluation based on mRNA expression data.